Hikma Pharmaceuticals PLC (HKMPF)
OTCMKTS · Delayed Price · Currency is USD
26.38
0.00 (0.00%)
At close: Jul 30, 2025
Hikma Pharmaceuticals Employees
Hikma Pharmaceuticals had 9,500 employees as of December 31, 2024. The number of employees increased by 400 or 4.40% compared to the previous year.
Employees
9,500
Change (1Y)
400
Growth (1Y)
4.40%
Revenue / Employee
$329,158
Profits / Employee
$37,789
Market Cap
5.66B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9,500 | 400 | 4.40% |
Dec 31, 2023 | 9,100 | 300 | 3.41% |
Dec 31, 2022 | 8,800 | 100 | 1.15% |
Dec 31, 2021 | 8,700 | 100 | 1.16% |
Dec 31, 2020 | 8,600 | 0 | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
Endo, Inc. | 3,116 |
Tian'an Technology Group | 8 |
Elite Pharmaceuticals | 68 |
Glass House Brands | 374 |
CytoDyn | 9 |
Northwest Biotherapeutics | 25 |
American Oncology Network | 1,914 |
Silence Therapeutics | 116 |
Hikma Pharmaceuticals News
- 9 days ago - Hikma Pharmaceuticals: a quality compounder waiting for a catalyst - The Armchair Trader
- 4 weeks ago - Hikma receives FDA approval for TYZAVAN™ (Vancomycin Injection, USP) in the US - PRNewsWire
- 4 weeks ago - Hikma Pharmaceuticals to invest $1B by 2030 to expand US manufacturing, R&D - Seeking Alpha
- 4 weeks ago - Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines - PRNewsWire
- 2 months ago - Bio-Thera Solutions and Hikma Pharmaceuticals Announce FDA Approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection - PRNewsWire
- 2 months ago - Bio-Thera Solutions and Hikma Pharmaceuticals announce FDA approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection - PRNewsWire
- 3 months ago - Hikma acquires Novugen's FDA-approved ANDA for trametinib - PRNewsWire
- 5 months ago - Hikma Pharmaceuticals PLC (HKMPF) Q4 2024 Earnings Call Pre-Recorded (Transcript) - Seeking Alpha